Filtered By:
Management: Marketing
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 564 results found since Jan 2013.
As US Attorney, Labor Secretary Nominee Enabled Drug and Biotechnology Executives ' Impunity
The new Trump administration nominee for US Secretary of Labor is a former US Attorney for the southern district of Florida. In that role, he seemed to uphold the ideas that certain big corporations, particularly big pharmaceutical and biotechnology corporations, are too big to jail, and that top executives of big corporations should not be held accountable for their corporations ' actions.He had central involvement in three bigsettlements of charges of corporate misbehavior which held no individuals accountable for enabling, authorizing, directing or implementing the bad behavior. The settlements imposed only ...
Source: Health Care Renewal - February 21, 2017 Category: Health Management Tags: bribery Bristol-Myers-Squibb deception Donald Trump Genzyme GlaxoSmithKline impunity kickbacks legal settlements manipulating clinical research Sanofi-Aventis Source Type: blogs
Why I'm Excited for the ePharma Summit 2017
As a healthcare professional in training, I have had many opportunities to realize the potential for digital innovation within the healthcare industry. New technologies in this field have been emerging all over the world and spreading like wildfire to fill the gaps in the health system.My interest in the field of digital health and innovation has been growing over the years and has led me to take on several opportunities in this field. After conducting research on Mobile Health technology at the Juravinski Cancer Center, I was approached by ePharma with an opportunity to research and write about some of the most cutting-ed...
Source: ePharma Summit - February 14, 2017 Category: Pharmaceuticals Tags: Digital Health ePharma ePharma Summit Source Type: blogs
2017 Biosimilar Update
We have taken an interest in the growing biosimilars market in the United States. Recently, we covered the Friends of Cancer Research event, “The Future of the U.S. Biosimilars Market: Development, Education, and Utilization,” a half-day forum that brought together clinicians, originator and biosimilar drug sponsors, advocates, regulators, and payers in an attempt to tackle uncertainty surrounding the future of the United States biosimilars market. With now several biosimilars approved in the United States, there is an ever-growing interest in their approvals and further development. But heading into a new year, uncert...
Source: Policy and Medicine - February 7, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
A Cross-Section of Recent Work in the Aging Research Community
A recently published report from last year's Biomedical Innovation for Healthy Longevity conference, held in Russia, serves as a sampling of ongoing work in the field of aging research; a wide range of views on theories of aging are represented. One thing that strikes me from a review of the topics is that few of the people involved are working on anything related to rejuvenation, or, setting aside the much-needed consideration of biomarkers of biological age, any other projects with near term practical applications likely to significantly extend life. For the most part this is a field concerned with investigation, develop...
Source: Fight Aging! - February 7, 2017 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs
Purging Healthcare of Unnatural Acts
BY UWE REINHARDT
Everyone knows (or should know) that forcing a commercial health insurer to write for an individual a health insurance policy at a premium that falls short of the insurer’s best ex ante estimate of the cost of health care that individual will require is to force that insurer into what economists might call an unnatural act.
Remarkably, countries that rely on competing private health insurers to operate their universal, national health insurance systems all do just that. They allow each insurer to set the premium for a government-mandated , comprehensive benefit package, but require that each insurer “...
Source: The Health Care Blog - January 31, 2017 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Uwe Reinhardt Source Type: blogs
Will Trump ' s Leadership Picks Smack Down Health Care? - A Drug Company Lobbyist, an Entrepreneur Who Wants to Weaken Drug Testing, and a Mysterious Billionaire Who Settled Fraud Charges
President Trump in hisinauguration speech promised to reach out to " struggling families " and to benefit " American workers and American families, " and promised all Americans " you will never be ignored again. " Yet the Trump transition team, and now presidential administration continues to consider individuals for health care policy leadership roles remarkable for theirconflicts of interest, which often did not merely arise from small financial transactions but from their roles as corporate insiders, and in some cases, association with dubiously ethical practices. They are particularly unremarkable for their...
Source: Health Care Renewal - January 27, 2017 Category: Health Management Tags: conflicts of interest Covidien Donald Trump executive compensation fraud Medtronic revolving doors Source Type: blogs
Fact Checking Puzzling Criticisms of a " Puzzling " DTC Study Proposed by FDA
I get periodic emails from Bob Ehrlich, Chairman of DTC Perspectives, Inc., giving his opinion on various direct-to-consumer (DTC) advertising issues.Although I often do not agree with Ehrlich on many issues, I value his perspective and often respond to him via this blog (read, for example,"Are We at the Saturation Point Viz-a-Viz Celebrity Pharma Endorsements?"). We've even had a head-to-head podcast debate (listen to"Are Drug Marketers an Endangered Species?").In a recent email missive, Ehrlich calls FDA ’s recently proposed study of deception in DTC ads (read “Another FDA Study: Can HCPs and ...
Source: Pharma Marketing Blog - January 15, 2017 Category: Pharmaceuticals Tags: Bob Ehrlich DTC Advertising FDA Study Source Type: blogs
Why Do People Believe Drugs Are Too Expensive?
We have long heard from the media that the pharmaceutical industry “over charges” for prescription drugs and “makes money at the sake of those who can least afford it.” Public examples such as Turing, Mylan, and Valeant helped drive those narratives home. However, a poll done by the Kaiser Family Foundation (KFF) found that may not be the case. The polls were done throughout 2015 and 2016 and were related to public opinion on prescription drugs and their prices.
Perhaps one of the most interesting findings in the entire report was that seventy-seven percent of the public says the cost of prescription drugs ...
Source: Policy and Medicine - December 20, 2016 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Breaking Down The Final 2018 Letter To Issuers
Editor’s note: The final 2018 Letter To Issuers In The Federally Facilitated Maketplaces, discussed below, was issued in conjunction with the final 2018 Benefit and Payment Parameters rule, discussed here and here.
On December 16, 2016, the Centers for Medicare and Medicaid Services (CMS) at the Department of Health and Human Services (HHS) released its final 2018 Letter to Issuers in the Federally Facilitated Marketplaces (FFM). CMS releases a letter each year to insurers that offer coverage through the FFM or through state-based marketplaces that use the Healthcare.gov platform (SBM-FP), laying out the ground rule...
Source: Health Affairs Blog - December 19, 2016 Category: Health Management Authors: Timothy Jost Tags: Following the ACA Insurance and Coverage Payment Policy Source Type: blogs
The Most Exciting Medical Technologies of 2017
It is almost a tradition for me to publish predictions for the coming year. I do not mean to disappoint you this year either, so here you find some thoughts about the top medical technologies of 2017.
2016 was a rich year for medical technology. Virtual Reality. Augmented Reality. Smart algorithms analysing wearable data. Amazing technologies arrived in our lives and on the market almost every day. And it will not stop in the coming year.
The role of a futurist is certainly not making bold predictions about the future. No such big bet has taken humanity forward. Instead, our job is constantly analysing the trends shaping t...
Source: The Medical Futurist - December 15, 2016 Category: Information Technology Authors: nora Tags: Future of Medicine 3d printing AI artificial intelligence diabetes GC1 genetics Healthcare Innovation nutrigenomics Personalized medicine robotics wearables Source Type: blogs
Despite Long Record of Misadventures, Johnson and Johnson to Receive Award for " Ethical Leadership?! "
What does it take for a big pharmaceutical/ device/ biotechnology company to get an ethics award?Reported by Sheila Kaplan at Stat (but for subscribers only), and first noticed by Carl Elliott and justdiscussed on his Fear and Loathing in Bioethics blog, it appears that the giant Johnson and Johnson pharma/ device/ biotech company will get an award in " ethical leadership " from and " organization called Fellowships at Auschwitz for the Study of Professional Ethics, or FASPE. "The Stat report, quoted by Dr Elliott, stated:FASPE Chairman David Goldman, an attorney in New York, said he wasaware of the pharma giant ’s vario...
Source: Health Care Renewal - December 14, 2016 Category: Health Management Tags: crime health care ethics Johnson and Johnson legal settlements Source Type: blogs
Efficacy, We Don ' t Need No Stinking Proof of Efficacy - Says Apparent Trump Candidate to Lead FDA
DiscussionWe could do our usualrant about the revolving door here. Obviously, the revolving door pheonomenon is a serious conflict of interest, if not form of corruption, that should have no place in our government, particularly in its agencies that are concerned with health care. But there is a bigger issue here.So add anyone who might have to receive any medical treatment to the long list of people who should be worried about a future Trump administration. Maybe we would all be better off if Mr Tump finds something else to do for the next four years. Maybe he should stick tobeing executive p...
Source: Health Care Renewal - December 9, 2016 Category: Health Management Tags: adverse effects Donald Trump evidence-based medicine FDA revolving doors Source Type: blogs
21st Century Cures for Pharmaceutical Marketing
In what Public Citizen described as an"Early Gift for the Pharmaceutical Industry" (seehere), the Senate this week passed the 21st Century Cures Act (21st CC), which contains many provisions that will benefit the pharmaceutical industry and patients, according to many observers, including President Obama who said"We are now one step closer to ending cancer as we know it, unlocking cures for diseases like Alzheimer's..."The Act will also benefit pharma marketers and usher in a new era of pharmaceutical marketing. How so?Read more »
Source: Pharma Marketing Blog - December 9, 2016 Category: Pharmaceuticals Tags: 21st Century Cures Clinical Trials off-label promotion surrogates Source Type: blogs
Tips for a Successful Internship at LIVESTRONG
Mariah is a fall public relations and external affairs intern at the LIVESTRONG Foundation in Austin working with the public relations team and various other facets of the external affairs department. She will graduate in the spring with a Bachelor of Science in Public Relations and Mass Communication from Texas State University.As a public relations undergrad, I have spent most of my college career interning with for-profit PR firms in and around Austin. As I patiently searched the web for open positions that fit my criteria for a fall internship this summer, I knew I wanted to find a position that would offer me a work e...
Source: LIVESTRONG Blog - November 21, 2016 Category: Cancer & Oncology Authors: Guest Source Type: blogs
A Special Thanks to Scholastic, Inc. During this Season of Gratitude
by Michelle Bagwell (Intern),& Rebekkah Schear (staff)Cancer is a scary experience for anyone. But for a kid who has a family member, friend or other loved one diagnosed, it can mean uncertainty, questions and fear.When kids learn about cancer in school, they may learn the science behind it, but there ’s a lack of focus on what happens to people and communities when someone is affected by the disease. Schools often forget to teach about the emotional, practical or day-to-day impacts of cancer on families and communities. Moreover, most children are unprepared to cope with the diagnosis of a par ent, sibling, friend o...
Source: LIVESTRONG Blog - November 20, 2016 Category: Cancer & Oncology Authors: Rebekkah Schear (LIVESTRONG Staff) Source Type: blogs
